For years, the conversation around heart health has centered on one number: LDL cholesterol. Keep that low, the thinking goes, and your cardiovascular risk stays manageable. But a growing body of research is challenging that assumption, pointing to a largely overlooked particle in the blood that can drive serious heart events even in people whose cholesterol looks perfectly controlled.
That particle is called lipoprotein(a), or Lp(a), and it may be one of the most consequential things your doctor has never tested you for.
What is lipoprotein(a)?
Lp(a) is a type of lipoprotein, meaning it is a molecule that carries cholesterol through the bloodstream. In structure, it closely resembles LDL, the so-called bad cholesterol that most lipid-lowering medications are designed to target. But Lp(a) behaves differently, and standard cholesterol treatments do not lower it the way they lower LDL.
What makes Lp(a) particularly significant is that it appears to contribute to cardiovascular risk independently. Even in patients who are already on treatment and have their LDL well under control, elevated Lp(a) may leave them exposed to what researchers call residual risk, an ongoing vulnerability that standard care simply does not address.
What a major new study found
A recent study analyzed blood samples from more than 20,000 adults aged 40 and older, drawn from three large U.S. National Institutes of Health trials. Participants were grouped based on their Lp(a) levels and whether they already had existing heart disease. Researchers then tracked major adverse cardiovascular events, including strokes and cardiovascular deaths, over a median follow up period of nearly four years.
The results were notable. About 7.3% of participants experienced a major cardiovascular event during the follow up period, and elevated Lp(a) levels were meaningfully associated with increased risk, particularly for stroke and cardiovascular death. The study identified a threshold of 175 nmol/L as a marker for significantly higher risk, a number that could help clinicians decide when to take more aggressive action.
One finding stood out as somewhat unexpected: the study did not establish a clear link between high Lp(a) and heart attack risk specifically, even as it confirmed associations with other serious outcomes. That distinction is still being examined by the research community.
Why lifestyle changes won’t fix this one
Unlike LDL cholesterol, which responds to diet, exercise, and medication, Lp(a) levels are largely determined at birth. Genetics account for roughly 70 to 90% of an individual’s Lp(a) level, primarily driven by variations in a gene called LPA. That means eating more salad or cutting out red meat is not going to move the needle in any meaningful way for people with genetically elevated levels.
This is part of what makes Lp(a) so medically interesting and so clinically challenging. It is a risk factor that patients cannot lifestyle their way out of, which is why identifying it early and managing surrounding risks becomes all the more important.
What experts recommend right now
An estimated 20% of the global population has elevated Lp(a), yet routine testing remains inconsistent. Measurement techniques vary, targeted treatments are still in development, and many physicians simply do not include it in standard lipid panels.
Cardiologists are increasingly calling for a change. The recommendation gaining traction is that all adults should be tested for Lp(a) at least once in their lifetime as a baseline cardiovascular risk assessment. For those who come back with elevated levels, the management approach shifts to aggressive control of everything else that can be controlled, including LDL reduction, blood pressure management, blood sugar regulation, regular cardiovascular monitoring, and lifestyle habits like a heart healthy diet, consistent physical activity, and avoiding tobacco and excess alcohol.
What comes next for Lp(a) research
The medical field is not standing still on this. Several emerging therapies specifically targeting Lp(a) are currently in development, and early results have been promising. If successful, these treatments could open the door to truly personalized cardiovascular care for the significant portion of the population carrying elevated levels without knowing it.
For now, the most important step is awareness. Anyone with a family history of cardiovascular disease, or who has experienced heart events despite otherwise well-managed cholesterol, has every reason to ask their doctor about Lp(a) testing. It is a single conversation that could meaningfully change the picture of what their actual heart risk looks like.
